Yunxia Dong

498 total citations
12 papers, 366 citations indexed

About

Yunxia Dong is a scholar working on Molecular Biology, Epidemiology and Cancer Research. According to data from OpenAlex, Yunxia Dong has authored 12 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Epidemiology and 3 papers in Cancer Research. Recurrent topics in Yunxia Dong's work include Liver Disease Diagnosis and Treatment (3 papers), MicroRNA in disease regulation (3 papers) and RNA Research and Splicing (3 papers). Yunxia Dong is often cited by papers focused on Liver Disease Diagnosis and Treatment (3 papers), MicroRNA in disease regulation (3 papers) and RNA Research and Splicing (3 papers). Yunxia Dong collaborates with scholars based in China and Australia. Yunxia Dong's co-authors include Jie Cao, Wei Cao, Jin Ren, Yong Sun, Qingming Ma, Ningning Ma, Xiaohan Chang, Likun Gong, Henglei Lu and Qian Wu and has published in prestigious journals such as Chemical Engineering Journal, Nanoscale and Journal of Hepatology.

In The Last Decade

Yunxia Dong

12 papers receiving 362 citations

Peers

Yunxia Dong
Clement Penny South Africa
Yanan Cui China
Yunxia Dong
Citations per year, relative to Yunxia Dong Yunxia Dong (= 1×) peers Yanfang Wang

Countries citing papers authored by Yunxia Dong

Since Specialization
Citations

This map shows the geographic impact of Yunxia Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yunxia Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yunxia Dong more than expected).

Fields of papers citing papers by Yunxia Dong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yunxia Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yunxia Dong. The network helps show where Yunxia Dong may publish in the future.

Co-authorship network of co-authors of Yunxia Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Yunxia Dong. A scholar is included among the top collaborators of Yunxia Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yunxia Dong. Yunxia Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Liu, Lijun, Qingming Ma, Yang Gao, et al.. (2023). Functional nano-systems for transdermal drug delivery and skin therapy. Nanoscale Advances. 5(6). 1527–1558. 93 indexed citations
2.
Zhang, Min, Renshuai Zhang, Yunxia Dong, et al.. (2023). Oxygen supplementation liposomes for rheumatoid arthritis treatment via synergistic phototherapy and repolarization of M1-to-M2 macrophages. Chemical Engineering Journal. 459. 141484–141484. 28 indexed citations
3.
Dong, Yunxia, Xiaoding Xu, Qian Wu, et al.. (2022). MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db/db mice via STAT1/HMGCS1 axis. Molecular Biomedicine. 3(1). 25–25. 11 indexed citations
4.
Dong, Yunxia, Ling Zhou, Qingming Ma, et al.. (2022). Iodinated cyanine dye-based nanosystem for synergistic phototherapy and hypoxia-activated bioreductive therapy. Drug Delivery. 29(1). 238–253. 30 indexed citations
5.
Zhang, Meng, Xiangyu Zhang, Kai Zhao, et al.. (2021). Assembly of gold nanorods with L-cysteine reduced graphene oxide for highly efficient NIR-triggered photothermal therapy. Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy. 266. 120458–120458. 21 indexed citations
6.
Xu, Xiaoding, et al.. (2021). MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice. Metabolism. 119. 154768–154768. 18 indexed citations
7.
Ma, Ningning, Lei Fan, Yunxia Dong, et al.. (2021). New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice. Pharmacological Research. 167. 105562–105562. 20 indexed citations
8.
Dong, Yunxia, Lei Fan, Qian Wu, et al.. (2021). GADD45β stabilized by direct interaction with HSP72 ameliorates insulin resistance and lipid accumulation. Pharmacological Research. 173. 105879–105879. 10 indexed citations
9.
Chang, Xiaohan & Yunxia Dong. (2021). CACNA1C is a prognostic predictor for patients with ovarian cancer. Journal of Ovarian Research. 14(1). 88–88. 18 indexed citations
10.
Dong, Yunxia, Wei Cao, & Jie Cao. (2021). Treatment of rheumatoid arthritis by phototherapy: advances and perspectives. Nanoscale. 13(35). 14591–14608. 42 indexed citations
11.
Fan, Lei, Rongtao Lai, Ningning Ma, et al.. (2020). miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder. Journal of Hepatology. 74(1). 8–19. 58 indexed citations
12.
Dong, Yunxia, Henglei Lu, Qiang Li, et al.. (2019). (5R)-5-hydroxytriptolide ameliorates liver lipid accumulation by suppressing lipid synthesis and promoting lipid oxidation in mice. Life Sciences. 232. 116644–116644. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026